Mizuho analyst Salim Syed lowered the firm’s price target on Kura Oncology (KURA) to $25 from $30 and keeps an Outperform rating on the shares. The firm, which moved Komzifti first-line sales starting in its model to 2029 from 2027, says execution, along with additional combination data, will remain important for the stock through 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KURA: